Borgeson Blake has filed a notice to sell 40,000 shares of Class A stock from Recursion Pharmaceuticals, Inc. This transaction, filed on November 3, 2026, is significant as it illustrates the ongoing trading activity among company executives in the biological products sector.

The filing indicates that Borgeson Blake, who serves as a director at Recursion Pharmaceuticals, will sell these shares at an aggregate market value of $155,200. This sale follows a series of transactions in recent months, where Blake has liquidated shares on multiple occasions.

Background

Recursion Pharmaceuticals, Inc. is a company incorporated in Delaware and operates within the biological products sector. The company, which trades on NASDAQ under the SEC file number 001-40323, is based in Salt Lake City, Utah. Borgeson Blake, identified by the Central Index Key (CIK) 0001856094, is actively involved in the company as a director.

What the Filing Says

The recent filing states, "Borgeson Blake intends to sell 40,000 shares of Class A stock, acquired as founders shares on September 19, 2017, as part of a compensation package." The sale is set to take place on the same day as the filing.

Impact

This transaction may affect other shareholders and stakeholders within Recursion Pharmaceuticals, as executive sales can influence market perception and stock performance. The filing does not specify how this sale may impact the broader market or competitors in the biological products sector.

What's Next

The filing does not say what happens next regarding the sale or any potential future transactions by Borgeson Blake.